Dynamics of complement activation in aHUS and how to monitor eculizumab therapy

Combined Complement Gene Mutations in Atypical Hemolytic Uremic Syndrome Influence Clinical Phenotype

(2013) E. Bresin et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

C3 glomerulopathy: consensus report

(2013) Matthew C. Pickering et al.   KIDNEY INTERNATIONAL

Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome

(2013) Mathieu Lemaire et al.   NATURE GENETICS

Eculizumab in Atypical Hemolytic–Uremic Syndrome

(2013)   NEW ENGLAND JOURNAL OF MEDICINE

Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome

(2013) C.M. Legendre et al.   NEW ENGLAND JOURNAL OF MEDICINE

Atypical Hemolytic Uremic Syndrome

(2013) David Kavanagh et al.   SEMINARS IN NEPHROLOGY

A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function

(2012) L. T. Roumenina et al.   BLOOD

STEC-HUS, atypical HUS and TTP are all diseases of complement activation

(2012) Marina Noris et al.   Nature Reviews Nephrology

Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies

(2012) Julien Zuber et al.   Nature Reviews Nephrology

Age-Related Penetrance of Hereditary Atypical Hemolytic Uremic Syndrome

(2011) Maren Sullivan et al.   ANNALS OF HUMAN GENETICS

Alternative complement pathway assessment in patients with atypical HUS

(2011) Lubka T. Roumenina et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Alternative Pathway Activation of Complement by Shiga Toxin Promotes Exuberant C3a Formation That Triggers Microvascular Thrombosis

(2011) M. Morigi et al.   JOURNAL OF IMMUNOLOGY

Atypical hemolytic uremic syndrome

(2011) Chantal Loirat et al.   Orphanet Journal of Rare Diseases

Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome

(2011) Marcus Weitz et al.   PEDIATRIC NEPHROLOGY

Relative Role of Genetic Complement Abnormalities in Sporadic and Familial aHUS and Their Impact on Clinical Phenotype

(2010) M. Noris et al.   Clinical Journal of the American Society of Nephrology

Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation

(2010) Rubén Martínez-Barricarte et al.   JOURNAL OF CLINICAL INVESTIGATION

The Development of Atypical Hemolytic Uremic Syndrome Depends on Complement C5

(2010) E. G. de Jorge et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Epidemiological Approach to Identifying Genetic Predispositions for Atypical Hemolytic Uremic Syndrome

(2009) Maren Sullivan et al.   ANNALS OF HUMAN GENETICS

Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome

(2009) L. T. Roumenina et al.   BLOOD

Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome

(2009) I. Moore et al.   BLOOD

Thrombomodulin Mutations in Atypical Hemolytic–Uremic Syndrome

(2009) Mieke Delvaeye et al.   NEW ENGLAND JOURNAL OF MEDICINE

Atypical Hemolytic–Uremic Syndrome

(2009) Marina Noris et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome

(2008) V. Fremeaux-Bacchi et al.   BLOOD

The Complement Factor H R1210C Mutation Is Associated With Atypical Hemolytic Uremic Syndrome

(2008) R. Martinez-Barricarte et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY